Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 31, 2025Open Access

Pitavastatin counteracts venetoclax resistance mechanisms in acute myeloid leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

DFDavid A. FrumanRBRoberta BuonoUniversity of California, IrvineDJDennis JuarezUniversity of California, Irvine

Discussion

Loading...

Member takes

Implication

Cellular analysis shows apoptosis from pitavastatin treatment in acute myeloid leukemia, suggesting a strategy to counter venetoclax resistance mechanisms.

Key Points

  • Pitavastatin treatment promotes apoptosis in acute myeloid leukemia cells, counteracting venetoclax resistance.
  • Cytotoxic activity observed at clinically achievable concentrations in TP53 or FLT3 mutant cell lines.
  • The approach involves targeting resistance mechanisms and improving apoptosis through mitochondrial metabolism.
  • These findings highlight the potential of pitavastatin as a combinatorial therapy to enhance treatment outcomes in AML.

Cite This Study

Fruman et al. (2025) studied this question.

synapsesocial.com/papers/6903fee5b25c631a4265fce9https://doi.org/10.1101/2025.10.27.684888
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia2015 · 1,936 citations
  2. 2Statins increase hepatic cholesterol synthesis and stimulate fecal cholesterol elimination in mice2016 · 143 citations
  3. 3Synthesis and evaluation of potent, highly-selective, 3-aryl-piperazinone inhibitors of protein geranylgeranyltransferase-I2006 · 53 citations
  4. 4Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors2023 · 14 citations